NR4A1 and breast cancer: BC is a very heterogeneous disease, clinically distinguished into several subtypes according to the expression of hormone receptors (HRs) and the human epidermal growth factor receptor 2 (HER-2) status: luminal BC, HER-2 positive BC, and triple-negative BC (TNBC).